ArticleScientific reports2019
Bone loss caused by dopaminergic degeneration and levodopa treatment in Parkinson's disease model mice.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 48 citations in OpenAlex.
- Generalized osteoporosis but not axial osteopenia is associated with cognitive impairment in Parkinson's disease.Annals of medicine · 2026Article
- MicroRNA-127-3p Inhibits In Vitro Osteogenesis and Dampens Trauma-Induced Heterotopic Ossification In Vivo.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2026Article
- Brain-bone axis dysregulation: Biological code underlying the bidirectional association between depression and musculoskeletal disorders.Journal of orthopaedic translation · 2026Review
- Orthopedic manifestations, complications, and outcomes for arthroplasty in patients with Parkinson disease.Bulletin of the Hospital for Joint Disease (2013) · 2025Review
- Brain-Bone Axis in Physiological and Pathological Conditions.International journal of molecular sciences · 2025Review
- The Role of Oral and Gut Microbiota in Bone Health: Insights from Bacterial Extracellular Vesicles.Microorganisms · 2025Review
- Mouse model of anti-RANKL discontinuation reveals reduced bone mass and quality through disruption of bone remodeling.Bone research · 2025Article
- Bone health in Parkinson's disease: a comprehensive review of bone involvement and its pathophysiological mechanisms.Frontiers in medicine · 2025Review
- Dopamine promotes osteogenic differentiation of PDLSCs by activating DRD1 and DRD2 during orthodontic tooth movement via ERK1/2 signaling pathway.Regenerative therapy · 2024Article
- Bone involvement in the early stages of Parkinson's disease: a case-control study.The Journal of international medical research · 2024Article
- Aggregated alpha-synuclein transcriptionally activates pro-inflammatory canonical and non-canonical NF-κB signaling pathways in peripheral monocytic cells.Molecular immunology · 2023Article
- Antipsychotic-induced bone loss: the role of dopamine, serotonin and adrenergic receptor signalling.Frontiers in cell and developmental biology · 2023Review
- Chaudhuri's Dashboard of Vitals in Parkinson's syndrome: an unmet need underpinned by real life clinical tests.Frontiers in neurology · 2023Review
- Dopamine, Immunity, and Disease.Pharmacological reviews · 2023Review
- Effects of a Resistance Training Protocol on Physical Performance, Body Composition, Bone Metabolism, and Systemic Homeostasis in Patients Diagnosed with Parkinson's Disease: A Pilot Study.International journal of environmental research and public health · 2022Article
- Single-cell transcriptomics identifies premature aging features of TERC-deficient mouse brain and bone marrow.GeroScience · 2022Article
- Height and nigral neuron density in Parkinson's disease.BMC neurology · 2022Article
- Acromion stress fracture in an elderly cane walker with Parkinson's disease: a case report.JSES reviews, reports, and techniques · 2021Article
- [Characteristics of geriatric and somatic status in patients with osteoporosis].Problemy endokrinologii · 2021Article
- Proteomic and genomic analysis of acid dentin lysate with focus on TGF-β signaling.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating evidence have shown the association of Parkinson's disease (PD) with osteoporosis. Bone loss in PD patients, considered to be multifactorial and a result of motor disfunction, is a hallmark symptom that causes immobility and decreased muscle strength, as well as malnutrition and medication. However, no known experimental evidence has been presented showing deleterious effects of anti-PD drugs on bone or involvement of dopaminergic degeneration in bone metabolism. Here, we show that osteoporosis associated with PD is caused by dopaminergic degeneration itself, with no deficit of motor activity, as well as treatment with levodopa, the current gold-standard medication for affected patients. Our findings show that neurotoxin-induced dopaminergic degeneration resulted in bone loss due to accelerated osteoclastogenesis and suppressed bone formation, which was associated with elevated prolactin. On the other hand, using an experimental model of postmenopausal osteoporosis, dopaminergic degeneration did not result in exacerbation of bone loss due to estrogen deficiency, but rather reduction of bone loss. Thus, this study provides evidence for the regulation of bone metabolism by the dopaminergic system through both gonadal steroid hormone-dependent and -independent functions, leading to possible early detection of osteoporosis development in individuals with PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.